<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Hutchmed (china) Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/hutchmed-china-ltd</link>
    <description>Latest news and press releases for Hutchmed (china) Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 10:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/hutchmed-china-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia</title>
      <link>https://6ix.com/company/hutchmed-china-ltd/news/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-and-breakthrough-designation-for-sovleplenib-for-the-treatment-of-warm-antibody-autoimmune-hemolytic-anemia</link>
      <guid isPermaLink="true">https://6ix.com/company/hutchmed-china-ltd/news/hutchmed-announces-nda-acceptance-in-china-with-priority-review-status-and-breakthrough-designation-for-sovleplenib-for-the-treatment-of-warm-antibody-autoimmune-hemolytic-anemia</guid>
      <pubDate>Wed, 29 Apr 2026 10:00:00 GMT</pubDate>
      <description>HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Adminis</description>
    </item>
  </channel>
</rss>